Google
REPL — REPLIMUNE GROUP INC (Healthcare >> Biotechnology)
REPL FAQ
What is REPL's ROE?
REPLIMUNE GROUP INC reports a Return on Equity (ROE) of -149.55%.
What is REPL's dividend yield?
REPLIMUNE GROUP INC offers a dividend yield of 0.00%.
What is REPL's Deepscope Quality Score?
Deepscope rates REPL's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy REPL?
Deepscope's AI Timing Score for REPL is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does REPL belong to?
REPLIMUNE GROUP INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.98
Price
1.11
(12.51%)
Day Change
|
|
|---|
REPL, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 43 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.98 |
| PBV / Sector |
3.53 / 4.48
|
| Earning Per Share | -4.23 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
58.27 M
|
| Average 1W Daily Value |
138.72 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:23:58 |
| Symbol | REPL |
| Name | REPLIMUNE GROUP INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 82.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 743.15 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 500 Unicorn Park Drive, Woburn, MA, United States, 01801
Phone: 781 222 9600
Website: https://www.replimune.com
Employees: 479
Sector: Healthcare >> Biotechnology
Description: Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
